Skip to main content

Rakovina Therapeutics Announces Results from 2023 Annual General Meeting

VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2023 annual general meeting of shareholders held on June 28, 2023 (the “Meeting”).

All four members of the Company’s board of directors named as nominees in its management information circular (the “Circular”) were re-elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia and Michael Liggett.

Additional voting results from the Meeting include: (i) the shareholders approved the appointment of Davidson & Company LLP as the Company’s auditor until the next annual meeting; and (ii) the shareholders approved the Company’s existing omnibus equity incentive plan as set out in the Circular.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at: www.rakovinatherapeutics.com.

Additional Information

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact:

 
Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: info@rakovinatherapeutics.com
Investor Relations Contact
IR@rakovinatherapeutics.com

Media Contact
MEDIA@rakovinatherapeutics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.